Skip to main content
SpringerLink
Log in

Adalimumab/immunosuppressants/infliximab

Various infections: 14 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Lawrance IC, Radford-Smith GL, Bampton PA, Andrews JM, Tan P-K, Croft A, Gearry RB, Florin THJ.Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: An Australian and New Zealand experience. Journal of Gastroenterology and Hepatology 25: 1732-1738, No. 11, Nov 2010. Available from: URL: http://dx.doi.org/10.1111/j.1440-1746.2010.06407.x - Australia

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adalimumab/immunosuppressants/infliximab. React. Wkly. 1332, 7 (2010). https://doi.org/10.2165/00128415-201013320-00019

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201013320-00019

Keywords

Search

Navigation